CR20170234A - Composiciones de antibiótico - Google Patents
Composiciones de antibióticoInfo
- Publication number
- CR20170234A CR20170234A CR20170234A CR20170234A CR20170234A CR 20170234 A CR20170234 A CR 20170234A CR 20170234 A CR20170234 A CR 20170234A CR 20170234 A CR20170234 A CR 20170234A CR 20170234 A CR20170234 A CR 20170234A
- Authority
- CR
- Costa Rica
- Prior art keywords
- solutions
- acetyl
- amino acid
- antibiotic compositions
- vancomycin
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 2
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- 150000003862 amino acid derivatives Chemical class 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- -1 for example Chemical compound 0.000 abstract 1
- KTHDTJVBEPMMGL-GSVOUGTGSA-N n-acetylalanine Chemical compound OC(=O)[C@@H](C)NC(C)=O KTHDTJVBEPMMGL-GSVOUGTGSA-N 0.000 abstract 1
- 239000003186 pharmaceutical solution Substances 0.000 abstract 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076400P | 2014-11-06 | 2014-11-06 | |
| US201562168749P | 2015-05-30 | 2015-05-30 | |
| PCT/EP2015/075918 WO2016071495A1 (en) | 2014-11-06 | 2015-11-06 | Glycopeptide compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170234A true CR20170234A (es) | 2018-01-15 |
Family
ID=54478023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170234A CR20170234A (es) | 2014-11-06 | 2015-11-06 | Composiciones de antibiótico |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US10188697B2 (en:Method) |
| EP (4) | EP4147710A1 (en:Method) |
| JP (2) | JP6797795B2 (en:Method) |
| KR (2) | KR102763211B1 (en:Method) |
| CN (1) | CN107073072B (en:Method) |
| AU (1) | AU2015341763B2 (en:Method) |
| BR (1) | BR112017009405B1 (en:Method) |
| CA (1) | CA2964524A1 (en:Method) |
| CL (1) | CL2017001139A1 (en:Method) |
| CO (1) | CO2017005391A2 (en:Method) |
| CR (1) | CR20170234A (en:Method) |
| CY (2) | CY1122960T1 (en:Method) |
| DK (2) | DK3215173T3 (en:Method) |
| EA (1) | EA035368B1 (en:Method) |
| ES (2) | ES2852550T3 (en:Method) |
| HR (2) | HRP20200101T1 (en:Method) |
| HU (2) | HUE053347T2 (en:Method) |
| IL (1) | IL252120B (en:Method) |
| MX (1) | MX387229B (en:Method) |
| NZ (1) | NZ731955A (en:Method) |
| PH (1) | PH12017500720A1 (en:Method) |
| PL (2) | PL3542812T3 (en:Method) |
| PT (2) | PT3542812T (en:Method) |
| RS (2) | RS59851B1 (en:Method) |
| SA (1) | SA517381446B1 (en:Method) |
| SG (1) | SG11201703568WA (en:Method) |
| SI (2) | SI3215173T1 (en:Method) |
| TN (1) | TN2017000182A1 (en:Method) |
| WO (1) | WO2016071495A1 (en:Method) |
| ZA (1) | ZA201702767B (en:Method) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ731955A (en) | 2014-11-06 | 2023-07-28 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| EP3393491B1 (en) * | 2015-12-24 | 2025-04-16 | Universiteit Leiden | Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject |
| CA3021935A1 (en) * | 2016-05-09 | 2017-11-16 | Xellia Pharmaceuticals Aps | Stabilized glycopeptide antibiotic formulations |
| EP3544616A4 (en) * | 2016-11-23 | 2020-12-09 | Gufic Biosciences Limited | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN |
| JP7118412B2 (ja) * | 2017-07-31 | 2022-08-16 | 東洋製薬化成株式会社 | バンコマイシン懸濁液充填カプセル製剤 |
| CN109725101B (zh) * | 2017-10-31 | 2021-11-19 | 正大天晴药业集团股份有限公司 | 盐酸特拉万星原料中有关物质的检测方法 |
| CN109078001B (zh) * | 2018-09-21 | 2021-05-07 | 深圳浦瑞健康科技有限公司 | 一种万古霉素纳米脂质体组合物及其制备方法 |
| AU2020237983A1 (en) | 2019-03-08 | 2021-10-07 | Emphascience, Inc. | Stable pharmaceutical formulations of peptide and protein drugs |
| US12343373B2 (en) * | 2020-10-30 | 2025-07-01 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014969A1 (en) * | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014965A1 (en) * | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| WO2022234036A1 (en) * | 2021-05-07 | 2022-11-10 | Xellia Pharmaceuticals Aps | Oral liquid vancomycin formulations |
| CN115804832A (zh) * | 2021-09-14 | 2023-03-17 | 海南普利制药股份有限公司 | 一种万古霉素水溶液组合物 |
| JPWO2023171588A1 (en:Method) * | 2022-03-08 | 2023-09-14 | ||
| GB202207344D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
| GB202207345D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
| WO2024079224A1 (en) * | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
| US12070485B2 (en) | 2022-10-12 | 2024-08-27 | Xellia Pharmaceuticals Aps | Liquid dalbavancin compositions |
| WO2025006267A1 (en) * | 2023-06-26 | 2025-01-02 | Venn Biosciences Corporation | Peptide biomarkers for diagnosing primary sclerosing cholangitis or primary biliary cholangitis |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670258A (en) | 1984-02-10 | 1987-06-02 | Vanderbilt University | Storable prepackaged aqueous solutions of vancomycin |
| UA43323C2 (uk) | 1994-01-28 | 2001-12-17 | Елі Ліллі Енд Компані | Антибіотичні похідні глікопептидів, спосіб отримання та фармацевтична композиція |
| AU1407197A (en) | 1995-12-01 | 1997-06-19 | Eli Lilly And Company | Stable vancomycin hydrochloride solutions |
| JPH1180021A (ja) | 1997-09-02 | 1999-03-23 | Kayaku:Kk | バンコマイシン注射剤 |
| US6800608B2 (en) | 2001-06-22 | 2004-10-05 | Beckman Coulter, Inc. | Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator |
| US7022712B2 (en) * | 2002-03-26 | 2006-04-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Solubilization of weak bases |
| GB0212622D0 (en) | 2002-05-31 | 2002-07-10 | Natural Technologies Group Ltd | Bacterial transforming agent |
| CN1826129A (zh) * | 2002-07-09 | 2006-08-30 | 尖端医疗有限公司 | 与异亮氨酸硼脯氨酸化合物相关的方法和组合物 |
| AU2003248921A1 (en) | 2002-07-09 | 2004-01-23 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| US6900175B2 (en) | 2002-11-18 | 2005-05-31 | Vicuron Pharmaceuticals Inc. | Methods of administering dalbavancin for treatment of bacterial infections |
| PT1848413E (pt) | 2005-02-14 | 2014-07-18 | Venus Remedies Ltd | Terapia de combinação parentérica para afecções infecciosas com bactérias resistentes a fármacos |
| CN1857716A (zh) * | 2006-03-14 | 2006-11-08 | 浙江大学 | 注射用盐酸万古霉素及其制备方法 |
| JP2008201778A (ja) | 2007-01-25 | 2008-09-04 | Mochida Pharmaceut Co Ltd | バンコマイシン液状製剤 |
| EP2231191A2 (en) * | 2007-12-11 | 2010-09-29 | ConjuChem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
| JP2011080021A (ja) | 2009-10-09 | 2011-04-21 | Bridgestone Corp | 熱可塑性エラストマー組成物及びその成形体 |
| CA2836643C (en) * | 2011-05-19 | 2017-11-14 | Savara, Inc. | Dry powder vancomycin compositions and associated methods |
| US20150182667A1 (en) | 2012-08-08 | 2015-07-02 | Vanderbilt University | Composition with Biofilm Dispersal Agents |
| WO2014085526A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| US9616098B2 (en) | 2013-05-30 | 2017-04-11 | Scidose, Llc | Formulations of vancomycin |
| CN106573037A (zh) | 2014-03-14 | 2017-04-19 | 库蒂斯制药公司 | 用于万古霉素口服液的组合物和方法 |
| NZ731955A (en) | 2014-11-06 | 2023-07-28 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| CA3021935A1 (en) | 2016-05-09 | 2017-11-16 | Xellia Pharmaceuticals Aps | Stabilized glycopeptide antibiotic formulations |
| US12343373B2 (en) | 2020-10-30 | 2025-07-01 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
-
2015
- 2015-11-06 NZ NZ731955A patent/NZ731955A/en unknown
- 2015-11-06 CA CA2964524A patent/CA2964524A1/en active Pending
- 2015-11-06 DK DK15791287.4T patent/DK3215173T3/da active
- 2015-11-06 EA EA201790997A patent/EA035368B1/ru unknown
- 2015-11-06 PL PL19174849T patent/PL3542812T3/pl unknown
- 2015-11-06 EP EP22203229.4A patent/EP4147710A1/en active Pending
- 2015-11-06 PL PL15791287T patent/PL3215173T3/pl unknown
- 2015-11-06 CN CN201580060330.2A patent/CN107073072B/zh active Active
- 2015-11-06 SI SI201531067T patent/SI3215173T1/sl unknown
- 2015-11-06 DK DK19174849.0T patent/DK3542812T3/da active
- 2015-11-06 PT PT191748490T patent/PT3542812T/pt unknown
- 2015-11-06 HU HUE19174849A patent/HUE053347T2/hu unknown
- 2015-11-06 EP EP19174849.0A patent/EP3542812B1/en active Active
- 2015-11-06 WO PCT/EP2015/075918 patent/WO2016071495A1/en active Application Filing
- 2015-11-06 CR CR20170234A patent/CR20170234A/es unknown
- 2015-11-06 EP EP15791287.4A patent/EP3215173B8/en not_active Revoked
- 2015-11-06 RS RS20200080A patent/RS59851B1/sr unknown
- 2015-11-06 ES ES19174849T patent/ES2852550T3/es active Active
- 2015-11-06 TN TN2017000182A patent/TN2017000182A1/en unknown
- 2015-11-06 HU HUE15791287A patent/HUE049857T2/hu unknown
- 2015-11-06 MX MX2017005749A patent/MX387229B/es unknown
- 2015-11-06 EP EP20215453.0A patent/EP3834837A1/en active Pending
- 2015-11-06 SG SG11201703568WA patent/SG11201703568WA/en unknown
- 2015-11-06 PT PT157912874T patent/PT3215173T/pt unknown
- 2015-11-06 KR KR1020237020985A patent/KR102763211B1/ko active Active
- 2015-11-06 SI SI201531539T patent/SI3542812T1/sl unknown
- 2015-11-06 HR HRP20200101TT patent/HRP20200101T1/hr unknown
- 2015-11-06 JP JP2017523438A patent/JP6797795B2/ja active Active
- 2015-11-06 US US15/524,653 patent/US10188697B2/en active Active
- 2015-11-06 BR BR112017009405-3A patent/BR112017009405B1/pt active IP Right Grant
- 2015-11-06 ES ES15791287T patent/ES2769849T3/es active Active
- 2015-11-06 KR KR1020177015221A patent/KR102603756B1/ko active Active
- 2015-11-06 RS RS20210108A patent/RS61418B1/sr unknown
- 2015-11-06 AU AU2015341763A patent/AU2015341763B2/en active Active
-
2017
- 2017-04-18 PH PH12017500720A patent/PH12017500720A1/en unknown
- 2017-04-19 ZA ZA2017/02767A patent/ZA201702767B/en unknown
- 2017-05-01 SA SA517381446A patent/SA517381446B1/ar unknown
- 2017-05-04 IL IL252120A patent/IL252120B/en active IP Right Grant
- 2017-05-05 CL CL2017001139A patent/CL2017001139A1/es unknown
- 2017-05-26 CO CONC2017/0005391A patent/CO2017005391A2/es unknown
- 2017-11-30 US US15/827,719 patent/US10039804B2/en active Active
-
2018
- 2018-12-11 US US16/216,446 patent/US10849956B2/en active Active
-
2019
- 2019-11-07 US US16/677,057 patent/US11000567B2/en active Active
-
2020
- 2020-03-20 CY CY20201100266T patent/CY1122960T1/el unknown
- 2020-07-20 JP JP2020123671A patent/JP7032488B2/ja active Active
-
2021
- 2021-03-01 HR HRP20210342TT patent/HRP20210342T8/hr unknown
- 2021-03-29 US US17/215,675 patent/US11628200B2/en active Active
- 2021-04-09 CY CY20211100307T patent/CY1124011T1/el unknown
-
2022
- 2022-07-08 US US17/860,642 patent/US11517609B2/en active Active
-
2023
- 2023-01-06 US US18/151,155 patent/US12161690B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20170234A (es) | Composiciones de antibiótico | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
| CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
| CL2016002772A1 (es) | Composiciones de insulina de rápida acción | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2016001266A1 (es) | Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo. | |
| BR112018002983A2 (pt) | composição compreendendo uma lactama e um álcool | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX382747B (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias. | |
| CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
| MX2020004205A (es) | Composiciones antibioticas de ceftolozano. | |
| MX376628B (es) | Composiciones para el cuidado bucal. | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| BR112016023899A2 (pt) | composições compreendendo derivados de osteopontina para a inibição do crescimento do cabelo | |
| BR112017001888A2 (pt) | formulações biológicas para instilação intravesical | |
| MX2019007361A (es) | Composiciones para el cuidado bucal. | |
| GT201300225A (es) | Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia | |
| CL2016003095A1 (es) | Péptidos como agonistas de la oxitocina | |
| GB2543709A (en) | Pharmaceutical agent | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| CR20140489A (es) | Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t |